+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Assessing risks and benefits of erythropoiesis stimulating agents (ESAs) by tumor type in advanced solid tumor patients (ST): A meta-analysis of 16 randomized controlled trials (RCTs) including 4,646 patients



Assessing risks and benefits of erythropoiesis stimulating agents (ESAs) by tumor type in advanced solid tumor patients (ST): A meta-analysis of 16 randomized controlled trials (RCTs) including 4,646 patients



Journal of Clinical Oncology 26(15_Suppl): 9541-9541



NlmCategory="UNASSIGNED">9541 Background: ESAs as supportive care agents remain controversial. Caution involving efficacy and safety resulted in 2 ODAC meetings and 2 FDA label revisions, including a black box warning; 2 Cochrane Group meta-analyses (MA) found ESA benefits to be only a 1-1.5g/dl Hb rise and a 1 unit transfusion reduction (Bohlius JNCI 2005, 2006). Quality of life and symptom benefit claims are no longer permitted, with only a 3-4% advantage (Osterborg JCO 2002) questioning clinical relevance. Such symptom improvement is as likely due to disease parameters or response to therapy as it is to modest Hb effects (Wisloff Eur J Hem 2005). To assess further potential risks of ESAs, we initiated a data review addressing objections to the Cochrane MA. We conducted an abstracted data MA using these criteria: phase III RCTs comparing ESAs to placebo or control; trials with a single tumor type or closely related cancer, to reduce heterogeneity (Het); trials in ST. Adjuvant or neoadjuvant studies were excluded due to inadequate survival data. CMA software v2 (Biostat, NJ) calculated combined thrombosis rates and survival HRs, using fixed and random effects models including Het testing. Sensitivity analyses by tumor type were performed. See table Conclusions: Benefits of ESAs in patients with ST are modest and risks substantial. This analysis exploring risks by disease type shows that significant thrombotic risk extends across all tumor types. Detrimental survival outcomes appear to be related to disease type, suggesting the possibility of different mechanisms contributing to this risk. While overall there is a significant negative impact on survival, breast and head and neck cancers account for this. Continued ESA use requires consideration of these outcomes and available alternatives (observation or transfusion). Patients should receive detailed information concerning potential risks and small benefits of ESAs. [Table: see text] [Table: see text].

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057238696

Download citation: RISBibTeXText

PMID: 27948156


Related references

Evaluating the safety of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer, lung cancer, and hematologic malignancies: A meta-analysis of randomized, controlled trials. Blood 110(11, Part 1): 1071A, 2007

The Use of Preoperative Erythropoiesis-Stimulating Agents ESAs in Patients Who Underwent Knee or Hip Arthroplasty A Meta-Analysis of Randomized Clinical Trials. 2013

The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials. Journal of Arthroplasty 28(9): 1463-1472, 2014

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer 76(3): 478-485, 2012

Tumor progression and mortality associated with administration of erythropoiesis stimulating agents (ESAs) to cancer patients: Is toxicity due to ESAs or elevated hemoglobin (Hgb) levels. Journal of Clinical Oncology 26(15_Suppl): 11115-11115, 2016

Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Chinese Clinical Oncology 1(2): 19, 2012

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. Journal of Cancer Research and Clinical Oncology 138(2): 179-187, 2012

Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients. Plos One 12(12): E0189309, 2018

Does Adjuvant Treatment with Chinese Herbal Medicine to Antidiabetic Agents Have Additional Benefits in Patients with Type 2 Diabetes? A System Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine 2019: 1-14, 2019

Corticosteroids reduce mortality from alcoholic hepatitis in patients without encephalopathy a meta analysis of the randomized trials rcts including french trials. Hepatology 14(4 Part 2): 234A, 1991

Comparison of erythroid response (ER) rates to epoetin alfa (EPO) alone or in combination versus non-erythropoiesis-stimulating agents (non-ESAs) in treatment-naïve anemic MDS patients: A meta-analysis approach. Journal of Clinical Oncology 26(15_Suppl): 7094-7094, 2016

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. Journal of Experimental and Clinical Cancer Research 30: 54, 2011

Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Critical Care 19: 409, 2016

The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials. Clinical Drug Investigation 36(1): 27-39, 2016

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674): 1532-1542, 2009